Lantheus (NASDAQ:LNTH) Releases Earnings Results, Beats Estimates By $0.25 EPS

Lantheus (NASDAQ:LNTH) issued its earnings results on Thursday. The medical equipment provider reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25, FiscalAI reports. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. During the same period in the prior year, the firm earned $1.57 earnings per share. Lantheus’s revenue for the quarter was up 2.7% on a year-over-year basis.

Lantheus Stock Down 0.1%

LNTH traded down $0.12 during mid-day trading on Friday, reaching $100.95. 2,079,590 shares of the stock were exchanged, compared to its average volume of 1,643,055. Lantheus has a 1 year low of $49.67 and a 1 year high of $111.86. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.64 and a current ratio of 3.06. The stock has a market capitalization of $6.57 billion, a PE ratio of 24.38 and a beta of -0.03. The company has a 50 day moving average price of $104.09 and a two-hundred day moving average price of $87.98.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LNTH. UMB Bank n.a. boosted its holdings in shares of Lantheus by 104.1% in the 4th quarter. UMB Bank n.a. now owns 955 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 487 shares during the last quarter. Inceptionr LLC bought a new position in Lantheus during the fourth quarter valued at about $209,000. Advisory Services Network LLC purchased a new stake in Lantheus during the third quarter worth about $120,000. New Vernon Capital Holdings II LLC purchased a new stake in Lantheus during the third quarter worth about $147,000. Finally, iSAM Funds UK Ltd bought a new stake in Lantheus in the third quarter worth about $224,000. 99.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on LNTH shares. CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday. Mizuho decreased their target price on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Wednesday, July 29th. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. William Blair set a $102.50 price target on Lantheus in a research note on Monday. Finally, Weiss Ratings raised Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, July 31st. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Lantheus presently has an average rating of “Hold” and a consensus price target of $108.11.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.